Skip to main content

Foghorn Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

FHTX$2.04+9.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FOGHORN THERAPEUTICS INC.
Date: March 7, 2024By:/s/ Stephen DiPalma
Stephen DiPalma
Interim Chief Financial Officer(Principal Accounting and Financial Officer)

SIGNATURES AND POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints Adrian Gottschalk and Allan Reine, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Adrian GottschalkPresident, Chief Executive Officer and Director(Principal Executive Officer)March 7, 2024
Adrian Gottschalk
/s/ Stephen DiPalmaInterim Chief Financial Officer(Principal Accounting and Financial Officer)March 7, 2024
Stephen DiPalma.
/s/ Scott BillerDirectorMarch 7, 2024
Scott Biller, Ph.D.
/s/ Douglas ColeDirectorMarch 7, 2024
Douglas Cole, M.D.
/s/ Simba GillDirectorMarch 7, 2024
Simba Gill, Ph.D.
/s/ Thomas Lynch Jr.DirectorMarch 7, 2024
Thomas Lynch Jr., M.D.
/s/ Adam KoppelDirectorMarch 7, 2024
Adam Koppel, M.D., Ph.D.
/s/ Michael MendelsohnDirectorMarch 7, 2024
Michael Mendelsohn, M.D.
/s/ B. Lynne ParshallDirectorMarch 7, 2024
B. Lynne Parshall, Esq.
/s/ Ian SmithDirectorMarch 7, 2024
Ian Smith
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.